What is the Wegovy pill?
Wegovy pills are the first oral GLP-1 receptor agonist treatment for weight loss. Youโll take them every day, alongside a healthy diet and exercise routine. This should help to support consistent weight loss.
Who can use Wegovy pills?
Wegovy is licensed for use by people with a BMI of 30 or higher, or with a BMI of 27 or higher if you also have a weight related health condition, like heart disease or diabetes.
What active ingredient is in Wegovy pills?
Semaglutide, a type of GLP-1 receptor agonist, is the active ingredient in both Wegovy pens and pills. It works by mimicking the action of a natural hormone called glucagon-like peptide-1 (GLP-1).
This hormone is normally released by your gut after youโve eaten. It tells your body to release insulin to bring your blood sugar levels back down, and sends signals to your brain to tell it that youโre full. It can also slow down how quickly food passes through your digestive system.1
How do Wegovy pills work?
Semaglutide binds to GLP-1 receptors in the same way your natural GLP-1 hormone does, mimicking its action. If your bodyโs production of GLP-1 is impaired, or if your natural GLP-1 isnโt as effective as it should be, you can end up eating more when you donโt need to, leading to overweight and obesity.2
By activating your GLP-1 receptors, Wegovy pills can help to quiet the โnoiseโ of hunger cues and cravings, as well as make you feel more full after eating. This means you should feel like eating less, which can support your weight loss journey.
What doses of Wegovy pill are there?
Wegovy pills come in four doses. The lowest dose is 1.5 mg, then 4 mg, then 9 mg, and the highest dose is 25 mg. Youโll begin by taking the starting dose of 1.5 mg for 30 days, and then begin to move up doses after that depending on how well you tolerate treatment.
Treated trusted source:
- Shah, M. and Vella, A. (2014). Effects of GLP-1 on appetite and weight. Reviews in endocrine & metabolic disorders, 15(3), pp.181โ187.
- Madsbad, S. (2014). The role of glucagon-like peptide-1 impairment in obesity and potential therapeutic implications. Diabetes, Obesity, and Metabolism. 16(1). pp. 9-21.
How we source info.
When we present you with stats, data, opinion or a consensus, weโll tell you where this came from. And weโll only present data as clinically reliable if itโs come from a reputable source, such as a state or government-funded health body, a peer-reviewed medical journal, or a recognised analytics or data body. Read more in our editorial policy.